To assess performance of the INKA approach, pTyr IP‐based phosphoproteomic data were generated and analyzed for four well‐studied cell lines with known oncogenic driver kinases: K562 chronic myeloid leukemia (CML) cells (BCR‐ABL fusion), SK‐Mel‐28 melanoma cells (mutant BRAF), HCC827‐ER3 lung carcinoma cells (mutant EGFR), and H2228 lung carcinoma cells (EML4‐ALK fusion). This evidence concerns the gene BRAF and lung carcinoma.